drug_type
RELEVANT_DRUG
intervention_type
Cellular gene therapy (CAR T)
drug_description
Adoptive cellular gene therapy using a patient’s T cells engineered with a piggyBac transposon to express an anti-CD19 chimeric antigen receptor; upon infusion, the cells target CD19+ B-lineage cells to deplete autoreactive clones and reduce autoantibodies in SLE.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are gene-modified with a piggyBac transposon to express an anti-CD19 chimeric antigen receptor; upon infusion they recognize CD19 on B-lineage cells and induce CAR-mediated activation and cytotoxicity, depleting CD19+ B cells (including autoreactive clones) and reducing autoantibodies in SLE.
drug_name
Autologous CD19 CAR T cells (piggyBac-engineered)
nct_id_drug_ref
NCT06150651